Eikon Therapeutics, Inc. Common Stock
EIKN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$346.01M
Close$
$-2.82
144.1% downside
Current Fair Value
144.1% downsideOvervalued by 144.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $346.01 Million |
|---|---|
| Enterprise Value | $455.22 Million |
| Earnings per Share | $-6.16 |
| Beta | 0.94 |
| Outstanding Shares | 54,148,887 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -1.15 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 0.8 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.55 |
| Debt to Equity | 0.54 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-1.58
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-1.74
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.24%▼ 48.02% |
|---|---|
| Total Invested | $5.40M▼ 98.44% |
| Investors Holding | 7▼ 71.00% |
About Eikon Therapeutics, Inc. Common Stock
484 employees
CEO: Roger Perlmutter
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of pro...